Residency · Residency · Neurosurgery
Subarachnoid Hemorrhage: Initial Management
Overview
Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating cerebrovascular emergency caused by rupture of an intracranial aneurysm in approximately 85% of cases. It accounts for 5-10% of all strokes but carries disproportionate morbidity and mortality, with a case fatality rate of 30-50%. Rapid diagnosis, stabilization, and early aneurysm treatment are critical to prevent rebleeding and secondary brain injury.
Epidemiology
The annual incidence of aSAH is 6-9 per 100,000 population, with peak age of 50-60 years and a female predominance of 1.6:1. Smoking is the strongest modifiable risk factor, followed by hypertension, heavy alcohol use, and sympathomimetic drug use. A first-degree relative with SAH increases risk 3-5 fold. The prevalence of unruptured intracranial aneurysms in the general population is 2-5%, though most never rupture. Annual rupture risk depends on aneurysm size and location.
Etiology
Approximately 85% of SAH cases are aneurysmal, caused by rupture of a berry or saccular aneurysm. About 10% are perimesencephalic or non-aneurysmal, a benign pattern confined to the prepontine and interpeduncular cisterns with negative angiography and excellent prognosis. The remaining 5% result from other causes including AVM, dural AVF, dissection, mycotic aneurysm, vasculitis, coagulopathy, or tumor hemorrhage.
Clinical Presentation
The hallmark presentation is the "worst headache of my life," a sudden-onset thunderclap headache reaching maximum intensity in seconds. A sentinel headache (minor warning leak) precedes major SAH in 10-40% of patients and is often misdiagnosed. Accompanying features include nausea, vomiting, photophobia, and neck stiffness (meningismus). Loss of consciousness occurs in 40-50% at onset. Focal neurological deficits depend on aneurysm location and associated hematoma: a CN III palsy suggests a posterior communicating artery aneurysm, while bilateral lower extremity weakness suggests an anterior communicating artery aneurysm with pericallosal hematoma. Seizures occur at onset in 6-16%. Terson syndrome (intraocular hemorrhage) results from the acute rise in intracranial pressure.
Grading Scales
Hunt and Hess Grade
Grade I is asymptomatic or mild headache. Grade II is severe headache with nuchal rigidity but no neurological deficit except cranial nerve palsy. Grade III is drowsiness, confusion, or mild focal deficit. Grade IV is stupor with moderate to severe hemiparesis and possible early decerebrate rigidity. Grade V is deep coma with decerebrate rigidity and a moribund appearance.
| Hunt-Hess Grade | Clinical Description | Approximate Mortality |
|---|---|---|
| I | Asymptomatic or mild headache | ~1% |
| II | Severe headache, nuchal rigidity, ± CN palsy | ~5% |
| III | Drowsy, confused, mild focal deficit | ~19% |
| IV | Stupor, moderate-severe hemiparesis | ~42% |
| V | Deep coma, decerebrate rigidity | ~77% |
World Federation of Neurosurgical Societies (WFNS) Grade
This scale is based on GCS and focal deficits. Grade I is GCS 15 without motor deficit. Grade II is GCS 13-14 without motor deficit. Grade III is GCS 13-14 with motor deficit. Grade IV is GCS 7-12. Grade V is GCS 3-6.
| WFNS Grade | GCS | Motor Deficit |
|---|---|---|
| I | 15 | Absent |
| II | 13-14 | Absent |
| III | 13-14 | Present |
| IV | 7-12 | Present or absent |
| V | 3-6 | Present or absent |
Modified Fisher Grade (Predicts Vasospasm Risk)
Grade 0 indicates no SAH and no intraventricular hemorrhage. Grade 1 is thin SAH without IVH. Grade 2 is thin SAH with IVH. Grade 3 is thick SAH without IVH. Grade 4 is thick SAH with IVH, carrying the highest vasospasm risk.
| Modified Fisher Grade | CT Findings | Vasospasm Risk |
|---|---|---|
| 0 | No SAH, no IVH | Minimal |
| 1 | Thin SAH, no IVH | Low |
| 2 | Thin SAH with IVH | Moderate |
| 3 | Thick SAH, no IVH | High |
| 4 | Thick SAH with IVH | Highest |
Diagnosis
Non-Contrast CT Head
Non-contrast CT has a sensitivity of approximately 95% within 6 hours of onset, decreasing to about 85% at 24 hours and declining further over subsequent days. The pattern of blood distribution may suggest the aneurysm location: blood in the anterior interhemispheric fissure suggests the anterior communicating artery, Sylvian fissure blood suggests MCA bifurcation, prepontine cistern blood suggests basilar tip or perimesencephalic pattern, and suprasellar cistern blood suggests ICA or posterior communicating artery.
Lumbar Puncture
LP is indicated when CT is negative but clinical suspicion remains high. Xanthochromia (yellow discoloration from bilirubin breakdown of hemoglobin) requires 6-12 hours to develop; spectrophotometry is more sensitive than visual inspection. Elevated opening pressure and an RBC count that does not clear across sequential tubes distinguishes SAH from a traumatic tap. LP can be negative within the first 6 hours after symptom onset.
CT Angiography (CTA)
CTA has sensitivity exceeding 95% for aneurysms 3 mm or larger and serves as the first-line vascular imaging for SAH. It identifies aneurysm location, size, morphology, and relationship to the parent vessel and branches. Multiple aneurysms are present in 15-20% of SAH patients.
Digital Subtraction Angiography (DSA)
DSA remains the gold standard for aneurysm detection. It is indicated when CTA is negative but SAH is confirmed. It reveals aneurysm morphology, collateral flow, and vasospasm. A repeat DSA should be performed in 1-2 weeks if the initial study is negative, as the aneurysm may be thrombosed or compressed.
<image> Non-contrast CT head showing diffuse thick subarachnoid hemorrhage filling the basal cisterns (suprasellar, ambient, and sylvian cisterns), interhemispheric fissure, and bilateral intraventricular hemorrhage in the lateral and third ventricles. An adjacent CTA reconstruction shows a saccular aneurysm at the anterior communicating artery complex. The Modified Fisher grading scale is illustrated with representative CT images for each grade (0-4). Radiological teaching illustration with labeled cisterns and grading criteria. </image>
Initial Management
Airway and Resuscitation
Patients with GCS of 8 or below or inability to protect the airway should be intubated. Hypotension and hypoxia must be avoided, targeting systolic blood pressure of 120-150 mmHg before aneurysm treatment. Rapid sequence intubation should use agents that minimize ICP elevation, avoiding succinylcholine if ICP is elevated.
Blood Pressure Management (Pre-Treatment)
The target systolic blood pressure is below 160 mmHg per AHA/ASA guidelines to reduce rebleeding risk. Preferred intravenous agents include nicardipine infusion, labetalol, and clevidipine. Precipitous drops should be avoided to maintain adequate cerebral perfusion, as aggressive BP reduction before aneurysm securing carries a theoretical risk of worsening ischemia.
Rebleeding Prevention
The rebleeding risk is 4-14% within the first 24 hours and is highest in the first 2-6 hours. Early aneurysm treatment within 24 hours of admission (ideally within 12 hours) is the most effective prevention strategy. Short-course antifibrinolytic therapy (tranexamic acid or aminocaproic acid for less than 72 hours) reduces rebleeding but does not improve overall outcomes and may increase thrombotic complications; it is used as a bridge until definitive aneurysm treatment. Other measures include bed rest, a quiet environment, stool softeners, and analgesia.
Hydrocephalus Management
Acute hydrocephalus occurs in 15-20% of patients from IVH or cisternal blood obstructing CSF pathways. An external ventricular drain is indicated for GCS decline with ventriculomegaly and should be placed before aneurysm treatment if acute hydrocephalus is present. The risk of rebleeding with EVD placement is minimal if CSF drainage is controlled.
Seizure Management
Prophylactic anticonvulsants are controversial; AHA/ASA guidelines suggest considering short-term prophylaxis. Levetiracetam is preferred over phenytoin, as phenytoin is associated with worse cognitive outcomes in SAH. Long-term prophylaxis is not recommended unless clinical seizures occur.
Medical Stabilization
Nimodipine 60 mg orally or via nasogastric tube every 4 hours for 21 days is proven to reduce poor outcomes from vasospasm. Its benefit is likely through neuroprotection rather than direct vasodilation. DVT prophylaxis with sequential compression devices should begin immediately, with pharmacologic prophylaxis added after aneurysm securing. Euvolemia is maintained while avoiding hypovolemia. Glucose control avoids hyperglycemia. Normothermia is targeted with active fever control. Pain is managed while avoiding excessive sedation.
Aneurysm Treatment (Overview)
The choice between microsurgical clipping and endovascular coiling depends on aneurysm and patient characteristics (detailed in the next lecture). Early treatment within 24 hours is standard to prevent rebleeding. For poor-grade patients (Hunt and Hess IV-V), early treatment is still generally recommended, as aggressive management of poor-grade patients has improved outcomes.
Complications of SAH (Overview)
Rebleeding carries the highest risk in the first 24 hours and is prevented by early aneurysm treatment. Vasospasm and delayed cerebral ischemia occur during days 4-14. Hydrocephalus may be acute (obstructive) or chronic (communicating), with 20-30% of patients requiring permanent shunt placement. Hyponatremia must be distinguished between cerebral salt wasting (volume-depleted) and SIADH (euvolemic/hypervolemic) based on volume status assessment. Cardiac complications include neurogenic stunned myocardium (takotsubo-like), troponin elevation, and arrhythmias. Neurogenic pulmonary edema results from the catecholamine surge.
<image> Flowchart for the initial management of aneurysmal SAH from emergency department presentation through the first 24 hours. Starting with clinical suspicion and CT diagnosis, branching through CTA for aneurysm identification, grading (Hunt-Hess, Modified Fisher), and simultaneous initiation of medical management (blood pressure control, nimodipine, seizure prophylaxis, EVD if needed). The pathway leads to early aneurysm treatment (clipping or coiling) within 24 hours. Key decision points for EVD placement, ICU admission, and rebleeding prevention are highlighted. Clean clinical algorithm with color-coded urgency levels. </image>
Clinical Pearls
The first rule of SAH management is to treat the aneurysm early, since rebleeding is the most preventable cause of death and early treatment within 24 hours is the standard of care. A negative CT does not rule out SAH; if clinical suspicion is high and CT is negative (especially more than 6 hours from onset), an LP should be performed, keeping in mind that xanthochromia requires 6-12 hours to develop. Nimodipine improves outcomes but does not angiographically reverse vasospasm; its benefit is likely neuroprotective, and it must be given for the full 21 days. Multiple aneurysms are present in 15-20% of SAH patients, and the culprit aneurysm is identified by the pattern of hemorrhage on CT, irregular morphology, and focal vasospasm. Cerebral salt wasting (not SIADH) is the more common cause of hyponatremia in SAH, requiring aggressive volume replacement with isotonic saline; fluid restriction (appropriate for SIADH) is dangerous in SAH patients. Hunt and Hess grade can improve with aggressive early management, so poor-grade patients should not be automatically triaged to comfort care. Cardiac troponin elevation in SAH reflects neurogenic myocardial injury rather than acute coronary syndrome; echocardiography distinguishes the two by showing regional wall motion abnormalities in a non-coronary distribution.
References
- Connolly ES Jr, et al. "Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage." Stroke. 2012;43(6):1711-1737.
- Diringer MN, et al. "Critical Care Management of Patients Following Aneurysmal Subarachnoid Hemorrhage: AHA/ASA Guideline." Stroke. 2011;42(6):1707-1730.
- Pickard JD, et al. "Effect of Oral Nimodipine on Cerebral Infarction and Outcome after Subarachnoid Haemorrhage." BMJ. 1989;298(6674):636-642.
- Hillman J, et al. "Immediate Administration of Tranexamic Acid and Reduced Incidence of Early Rebleeding after Aneurysmal Subarachnoid Hemorrhage." J Neurosurg. 2002;97(4):771-778.
- Hunt WE, Hess RM. "Surgical Risk as Related to Time of Intervention in the Repair of Intracranial Aneurysms." J Neurosurg. 1968;28(1):14-20.
